Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12 month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 3.9% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $9.12 on January 1st, 2023. Since then, TEVA shares have increased by 12.6% and is now trading at $10.27.
View the best growth stocks for 2023 here.

Teva Pharmaceutical Industries saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 25,020,000 shares, a decline of 20.5% from the December 31st total of 31,470,000 shares. Based on an average daily trading volume, of 9,750,000 shares, the days-to-cover ratio is currently 2.6 days.
View Teva Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Thursday, November, 3rd. The company reported $0.56 EPS for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The business earned $3.60 billion during the quarter, compared to analysts' expectations of $3.86 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 26.97%.

Teva Pharmaceutical Industries updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $2.40-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (1.94%), Harel Insurance Investments & Financial Services Ltd. (1.36%), Strs Ohio (0.11%), Assenagon Asset Management S.A. (0.09%), ARK Investment Management LLC (0.02%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $10.27.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.41 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

The company employs 37,537 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.